Studies
Every study, review and regulatory document in the collection, newest first. Each links to a page with its population, findings, funding and original source.
01Find
Filter studies
7 studies · Download as JSON
- Postmarketing Safety Signals and Medication-Use Risks of GLP-1-Based Therapies in Diabetes and Obesity: A Multi-Source Pharmacovigilance and Regulatory Evidence-Mapping StudyPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
- Glucagon-like Peptide-1 Receptor Agonist-Associated Injection Site and Dermatologic ReactionsPharmacovigilance · 2026 · Study tier 4 · Different population · Harm direction · Unreviewed automatic assessment
- Efficacy and safety of GLP-1 receptor agonists in Parkinson's disease: a systematic review and meta-analysis of randomized clinical trialsMeta-analysis · 2026 · Study tier 2 · Partial match · Null
- FDA prescribing information: Soliqua 100/33 (INSULIN GLARGINE AND LIXISENATIDE) - label effective 2026-03-18Regulatory document · 2026 · Not rated · Population unclear · Harm direction · Not peer reviewed · Unreviewed automatic assessment
- Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysisMeta-analysis · 2025 · Study tier 3 · Different population · Unclear · Unreviewed automatic assessment
- Trial of Lixisenatide in Early Parkinson's DiseaseRandomized trial · 2024 · Study tier 3 · Partial match · Benefit
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trialsMeta-analysis · 2021 · Study tier 1 · Different population · Benefit